Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Share-based Compensation (2022 - 2025)

Atara Biotherapeutics' Share-based Compensation history spans 4 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 74.05% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $9.8 million, down 63.88%, while the annual FY2025 figure was $9.8 million, 63.88% down from the prior year.
  • Share-based Compensation reached $1.5 million in Q4 2025 per ATRA's latest filing, up from $1.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.3 million in Q1 2022 to a low of $1.2 million in Q3 2025.
  • Average Share-based Compensation over 4 years is $8.5 million, with a median of $9.2 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: decreased 11.09% in 2023, then tumbled 80.92% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $11.4 million in 2022, then fell by 12.64% to $9.9 million in 2023, then tumbled by 41.11% to $5.8 million in 2024, then tumbled by 74.05% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Share-based Compensation are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $2.8 million (Q2 2025).